Articles tagged with Macular Degeneration
Researchers at Johns Hopkins Medicine have identified how smoking damages the eye and contributes to age-related macular degeneration (AMD). Cigarette smoke exposure causes epigenetic changes in retinal pigmented epithelial cells, leading to dysfunctional clusters and decreased gene expression.
A WVU research team is working to restore vision in people with inherited blindness due to genetic mutations in the Prominin1 gene. The team has observed encouraging early results using a mouse model and plans to investigate the therapy's effectiveness beyond initial restoration.
A new international study found that people with central vision loss can judge the motion of vehicles almost as accurately as those with normal vision. When both visual and auditory information were available, the two groups showed comparable accuracy in estimating the arrival time of approaching vehicles. The research, published in PL...
A novel clinical trial is exploring if a stem cell-derived retinal implant can not only stop the progression of dry age-related macular degeneration but also improve patients' vision. The implant uses lab-engineered RPE cells to replace damaged cells in the retina, potentially restoring central vision.
A study has revealed that reticular pseudodrusen, associated with increased risk of vision loss in AMD, are driven by pathways on chromosome 10 and not by genetic risks on chromosome 1. The discovery highlights the need for novel treatment approaches for different AMD subtypes.
Researchers have pinpointed specific genetic changes linked to reticular pseudodrusen deposits, driving vision loss in advanced age-related macular degeneration. This discovery provides a crucial lead for developing new drugs targeting these changes and potentially preventing vision loss before it begins.
A new study at Rice University found that individuals with age-related macular degeneration (AMD) can accurately estimate the arrival time of an approaching vehicle using a combination of visual and auditory cues. Despite impaired central vision, participants relied on both modalities to make collision judgments.
University of Minnesota researchers found that reducing chronic inflammation can significantly protect against age-related macular degeneration (AMD)-like pathology in preclinical models. The strategy aims to intervene before severe damage occurs, potentially delaying or preventing vision loss for those with early signs of AMD.
Spanish researchers at UMH have developed a new generation of visual neuroprosthesis capable of bidirectional communication with the cerebral cortex. The system uses a small external camera to capture images, which are processed electronically and converted into electrical stimulation patterns sent to the occipital cortex. Participants...
A cohort study found that GLP-1 receptor agonist use was associated with a reduced risk of developing nonexudative AMD, but not progression to exudative AMD in individuals with nonexudative AMD. This study may inform future randomized trials evaluating the ocular effects of GLP-1RAs in nondiabetic populations.
A wireless retinal implant has been shown to restore central vision in patients with advanced age-related macular degeneration (AMD), with 81% of participants achieving clinically meaningful improvements in visual acuity. The device converted light into electrical signals, stimulating remaining retinal cells and restoring visual inform...
The PRIMA device partially restored vision to 27 out of 32 participants in a clinical trial, allowing them to read with acuity equivalent to 20/42 vision. The device works by projecting images onto the retina via infrared light and converting them into electrical stimulation, enabling form vision.
A pioneering eye device has restored reading vision to people with sight loss, allowing them to read letters, numbers, and words through a prosthetic eye. The PRIMA chip operation involves an implant paired with augmented-reality glasses, enabling patients to regain their independence and confidence.
Researchers developed an mRNA vaccine that suppresses abnormal blood vessel growth in mouse models of age-related macular degeneration. The vaccine is as effective as current therapies and offers a convenient alternative to frequent eye injections.
A new eyedrop formula has shown promising results in delivering lutein, a protective antioxidant compound, to the retina to support retinal health and potentially slow or prevent damage. The formula uses nanotechnology called cubosomes to deliver drugs and has the potential to transform how we manage age-related macular degeneration.
Researchers are testing whether low-concentrate atropine drops can delay the onset of myopia in children. The study aims to reduce the risk of sight-threatening complications later in life by decreasing how nearsighted someone becomes.
A study found that more than half of the general population in the USA and Europe experience dry eyes, with only 20% of European patients and 17% of US patients receiving a diagnosis. The delay in seeking treatment is concerning, as early intervention can prevent inflammation and worsening symptoms.
Researchers have established apple snails as a system to study eye regeneration, which may hold the key for restoring vision due to damage and disease. The team discovered that the snail eye is anatomically similar to humans and can regrow itself, with genes such as pax6 playing a crucial role in development.
In a breakthrough study, researchers at the University of Rochester Medical Center found that microglia cells respond differently than neutrophils to photoreceptor damage in the retina. This discovery has high implications for treating vision loss caused by photoreceptor cell damage.
A new study found that older people with diabetes who do not control their blood sugar levels are three times more likely to develop eye disease than those with controlled blood sugar levels. High glucose levels were also linked to an increased risk of glaucoma and macular degeneration.
A new study found that increasing apolipoprotein M levels can slow or block progression of age-related macular degeneration, a leading cause of blindness in people over 50. The researchers also found that ApoM triggers a signaling pathway that breaks down cholesterol deposits.
Scientists have discovered that heparan sulfate in Bruch's membrane traps lipoproteins, leading to drusen formation and vision loss. Targeting this interaction may prevent or reverse early signs of AMD.
The use of GLP-1 receptor agonists among diabetes patients is associated with a higher risk of developing incident neovascular age-related macular degeneration. Further research is needed to understand the underlying mechanisms and trade-offs between benefits and risks.
Researchers found that an inexpensive HIV drug can improve vision in patients with diabetic macular edema (DME) more effectively and at a lower cost than existing treatments. The drug, lamivudine, is taken orally and may represent a game-changing option for millions of patients worldwide.
Researchers have developed a novel surgical technique to implant multiple tissue grafts in the eye's retina, expanding treatment options for dry AMD. The new method, which maintains eye pressure during graft insertion, promotes photoreceptor survival and regeneration of the choriocapillaris.
A new study from the University of Oklahoma is targeting cell communication in the hunt for therapies to slow macular degeneration. The research team is studying how cells in the retina communicate and whether the messages they send could be programmed to treat or slow AMD.
A new study found that treating aged mice with montelukast improved retinal health by reducing inflammation and boosting proteasome activity. This approach may offer a promising new way to slow age-related vision loss and protect eye health in older adults.
A new stem cell transplant treatment has shown promising results in clearing clinical safety hurdles for the treatment of wet age-related macular degeneration. The treatment involves removing abnormal blood vessels and transplanting stem cell-derived retinal cells to replace damaged or lost retinal cells.
Researchers demonstrate the effectiveness of Ziapin2 in restoring ON, OFF, and ON-OFF responses induced by light stimuli in retinas with retinitis pigmentosa. The molecule restores light-induced behavior and visual acuteness for up to two weeks without toxic or inflammatory effects.
A $6 million grant from the California Institute for Regenerative Medicine is driving research into a new treatment for dry age-related macular degeneration, a leading cause of blindness in older adults. The therapy aims to halt or reverse disease progression using stem cell-derived healthy retinal pigment epithelium cells.
Researchers have identified a new experimental drug that can bridge the gap between patients with wet age-related macular degeneration (AMD) and existing treatments. The drug, 32-134D, decreases levels of a key protein involved in AMD, leading to improved vision outcomes.
Researchers at Rensselaer Polytechnic Institute have developed a novel compound to treat dry age-related macular degeneration and Stargardt disease, both blindness-causing diseases. The compound has shown therapeutic potential in slowing down disease progression and preserving vision.
A new study found that consuming pistachios daily can significantly improve eye health by increasing macular pigment optical density due to the plant pigment lutein. Lutein may also benefit brain function by reducing oxidative stress and inflammation, supporting overall healthy aging.
Researchers have introduced DSFN to improve the speed and accuracy of diagnoses of retinal disorders. This AI-powered medical imaging technique combines retina images with vascular distribution information to accurately locate the fovea in complex clinical scenarios, enabling doctors to detect early signs of ocular diseases.
Scientists from Trinity College Dublin have developed a gene therapy that protects retinal ganglion cells and improves their function in animal models of glaucoma. The therapy has also been shown to increase oxygen consumption and ATP production in human retinal cells, indicating enhanced cell performance.
A research team at the University of Minnesota Medical School has identified small molecules that can reduce protein production linked to AMD. Blocking a cellular pathway, GSK3, may prevent or modify AMD with administration of a single drug.
Researchers found that taking AREDS2 supplements slows the expansion of geographic atrophy regions towards the central foveal region of the retina. The study suggests that antioxidant supplementation may slow central vision loss in people with late-stage dry AMD, supporting continued use of AREDS2 supplements.
Researchers have identified early changes in AMD patients that lead to measurable local vision loss. The study's findings could help improve treatment and monitoring of the disease, enabling new therapies and improved treatments for central blindness.
Researchers found that inhibiting telomerase, an enzyme related to cell growth and division, can suppress abnormal vascular growth in the retina. This discovery provides a potential alternative treatment option for wet AMD, which is currently treated with anti-VEGF injections.
A new AI model has been developed to improve clinical trial recruitment for eye disease, specifically Geographic Atrophy. The system identified almost twice as many candidates and with higher precision compared to conventional approaches, showing promise for overcoming a major obstacle in GA clinical trials.
Researchers have found a pioneering approach to combat age-related vision loss with a new therapy that boosts IRAK-M levels in retinal cells. The discovery offers a comprehensive treatment option for the millions of people affected by AMD.
Researchers at MCG's Vascular Biology Center have identified a new treatment target for age-related macular degeneration (AMD), a leading cause of blindness. Targeting the adenosine receptor 2A (Adora2a) may block excessive blood vessel growth and fibrosis, potentially offering a more efficient treatment than current therapies.
A phase II clinical study found that minocycline did not slow the expansion of geographic atrophy regions or vision loss in people with dry age-related macular degeneration. Previous studies have shown that minocycline can reduce inflammation and microglial activity in the eye, but it has not previously been tested for this condition.
Researchers develop a versatile imaging system for targeted spectroscopy in the eye fundus, allowing for continuous color imaging and spectral measurements. The system enables users to select targets and move them to any location within the eye fundus region without realignment or fixation changes.
Scientists at Johns Hopkins Medicine have identified a molecular pathway involving oxidative stress and the protein HIF-1 that contributes to both wet and dry age-related macular degeneration. Researchers found that while HIF-1 promotes blood vessel growth in retinal cells, it also protects against cell death in advanced dry AMD.
A new study by Anglia Ruskin University and University of Oxford highlights the lack of clinical research on severe sight impairment (SSI) among working-age individuals in the UK. The study finds that inherited retinal disorders, such as IRDs, are under-researched despite being a leading cause of SSI certifications in this population.
Researchers developed 'acoustic touch' smart glasses that translate visual information into distinct sound icons, enhancing the ability of blind or low-vision individuals to navigate their surroundings. The technology significantly improved object recognition and reaching abilities, empowering independence and quality of life.
A team of researchers at Utah State University has successfully created an in vitro model of Bruch's membrane, a layer in the retina that deteriorates with age. The model uses hagfish slime proteins to replicate the natural aging process and disease progression, providing a valuable tool for studying age-related macular degeneration.
Age-related macular degeneration (AMD) decreases essential fatty acid docosahexaenoic acid (DHA), limiting protective molecule formation and repair potential. The discovery may open new therapeutic avenues for AMD, particularly in females, who are more susceptible to retinal degeneration due to estrogen effects.
Researchers from Anglia Ruskin University have successfully grown retinal pigment epithelial cells on a nanofibre scaffold treated with fluocinolone acetonide, showing increased resilience and growth. This breakthrough technology has great potential for developing ocular tissue transplantation to treat age-related macular degeneration.
Researchers will explore characteristics of misplaced calcifications in eyes and brains, and their roles in AMD and AD. The team aims to examine calcifications at multiple levels, from atomic structures to aggregated morphologies, and their accumulation in cells and animals.
Researchers have developed a custom OCT setup that incorporates a vertical cavity surface emitting laser (VCSEL) diode, which could increase access to OCT imaging and help catch eye problems early. The system performed well in imaging the eye of a healthy volunteer and showed potential for use in biometric eye scanner systems.
Researchers at Duke-NUS Medical School have achieved significant vision recovery in experimental models of damaged retinas using stem cells. The study marks a promising step towards potentially restoring vision in eye diseases characterized by photoreceptor loss.
Researchers generated a POLDIP2 knockout ARPE-19 cell line and found reduced mitochondrial superoxide levels, consistent with upregulated SOD2. The study demonstrates a potential role of POLDIP2 in regulating oxidative stress in AMD.
A recent study from the National Eye Institute has discovered rare genetic variants that may be driving age-related macular degeneration (AMD), a chronic inflammatory response in the retina. The variants affect the stability of the membrane attack complex (MAC), which could lead to destructive inflammation and AMD progression.
UVA scientists have discovered a new contributor to abnormal blood vessel growth in the eye, which could lead to new treatments for macular degeneration and other vision loss conditions. The discovery identifies a key protein that determines VEGF levels, blocking it has reduced VEGF levels significantly without unwanted side effects.
Researchers discover gene therapy ophNdi1 that boosts mitochondrial performance in retinal ganglion cells, potentially treating glaucoma and age-related macular degeneration. The therapy shows protective effects in three models of mitochondrial dysfunction.
A research team led by Dr. Eddie Ma Chi-him identified a therapeutic small molecule M1 that increases mitochondrial dynamics and sustains long-distance axon regeneration, restoring visual functions in mice. Regenerated axons elicited neural activities and survived for four weeks after optic nerve injury.
In a mouse model of laser-induced CNV, RORα expression was highly increased in the choroidal/RPE complex post-laser, while loss or inhibition of RORα worsened CNV with increased lesion size and vascular leakage. RORα negatively regulates pathological CNV development by modulating angiogenic response and inflammatory environment.
Researchers have identified a new genetic risk factor for adult-onset macular degeneration by combining multiple maps. The study reveals that variations in the TRPM1 gene promoter alter LHX2 transcription factor binding, reducing gene activity and increasing disease risk. This finding advances our understanding of AMD's complex pathology.